"Spartacus: Blood and Sand" star requires additional treatment
Actor Andy Whitfield, the star of Spartacus: Blood and Sand, the hit show on the Starz cable network, has announced that he's pulling out of the show's second season in order to undergo aggressive treatment for relapsed non-Hodgkin's lymphoma.
Whitfield was originally diagnosed in March of 2010 with an unnamed subtype of NHL. In May, on completion of treatment, his doctors told him he was cancer-free.
In a statement, the 36 year old actor said "It's with a deep sense of disappointment that I must step aside from such an exceptional project as Spartacus and all the wonderful people involved. It seems that it is time for myself and my family to embark on another extraordinary journey."
Source
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
